Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Martínez Bonet, Marta ^a,b   Isabel Clemente, Maria ^a,b   Jesús Serramía, Maria ^a,b   Muñoz, Eduardo ^c   Moreno, Santiago ^d   Ángeles Muñoz Fernández, Maria ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; BRYOSTATIN; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; PANOBINOSTAT; ROMIDEPSIN;

CELL LINE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE; MACROPHAGE; MONOCYTE; PHYSIOLOGY; TIME FACTOR; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

ANTIBIOTICS, ANTINEOPLASTIC; BRYOSTATINS; CELL LINE; CELL SURVIVAL; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; HYDROXAMIC ACIDS; INDOLES; LYMPHOCYTES; MACROPHAGES; MONOCYTES; TIME FACTORS; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84946925503     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16445     Document Type: Article

References (52)

1. Battistini, A. & Sgarbanti, M. HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses 6, 1715-1758, doi: 10.3390/v6041715 (2014).
2. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295-1300 (1997).
3. Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291-1295 (1997).
4. Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 94, 13193-13197 (1997).
5. Stebbing, J., Gazzard, B. & Douek, D. C. Where does HIV live? N Engl J Med 350, 1872-1880, doi: 10.1056/NEJMra032395 (2004).
6. Carter, C. C. et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nature medicine 16, 446-451, doi: 10.1038/nm.2109 (2010).
7. Kulkosky, J. & Bray, S. HAART-persistent HIV-1 latent reservoirs: their origin, mechanisms of stability and potential strategies for eradication. Current HIV research 4, 199-208 (2006).
8. Margolis, D. M. Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS 6, 25-29, doi: 10.1097/COH.0b013e328341242d (2011).
9. Shirakawa, K., Chavez, L., Hakre, S., Calvanese, V. & Verdin, E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 21, 277-285, doi: 10.1016/j.tim.2013.02.005 (2013).
10. Xing, S. et al. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. Journal of virology 85, 6060-6064, doi: 10.1128/JVI.02033-10 (2011).
11. Doyon, G., Zerbato, J., Mellors, J. W. & Sluis-Cremer, N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. Aids 27, F7-F11, doi: 10.1097/QAD.0b013e3283570620 (2013).
12. Zhu, J. et al. Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep 2, 807-816, doi: 10.1016/j.celrep.2012.09.008 (2012).
13. Warrilow, D., Gardner, J., Darnell, G. A., Suhrbier, A. & Harrich, D. HIV type 1 inhibition by protein kinase C modulatory compounds. AIDS research and human retroviruses 22, 854-864, doi: 10.1089/aid.2006.22.854 (2006).
14. Kulkosky, J. et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98, 3006-3015 (2001).
15. Hamer, D. H. et al. Rational design of drugs that induce human immunodeficiency virus replication. Journal of virology 77, 10227-10236 (2003).
16. Mehla, R. et al. Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PloS one 5, e11160, doi: 10.1371/journal.pone.0011160 (2010).
17. del Real, G. et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. The Journal of experimental medicine 200, 541-547, doi: 10.1084/jem.20040061 (2004).
18. Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482-485, doi: 10.1038/nature11286 (2012).
19. Rasmussen, T. A., Tolstrup, M., Winckelmann, A., Ostergaard, L. & Sogaard, O. S. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother 9, 790-799, doi: 10.4161/hv.23202 (2013).
20. Yin, H., Zhang, Y., Zhou, X. & Zhu, H. Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells. Mol Biol Rep 38, 5071-5078, doi: 10.1007/s11033-010-0653-6 (2011).
21. Victoriano, A. F. et al. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression. FEBS Lett 585, 1103-1111, doi: 10.1016/j.febslet.2011.03.017 (2011).
22. Furumai, R. et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62, 4916-4921 (2002).
23. Zonder, J. A. et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res 7, 38-42 (2001).
24. Bullen, C. K., Laird, G. M., Durand, C. M., Siliciano, J. D. & Siliciano, R. F. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature medicine 20, 425-429, doi: 10.1038/nm.3489 (2014).
25. Reuse, S. et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 4, e6093, doi: 10.1371/journal.pone.0006093 (2009).
26. Perez, M. et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Current HIV research 8, 418-429 (2010).
27. Chen, L. F., Mu, Y. & Greene, W. C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 21, 6539-6548 (2002).
28. Rasmussen, T. A. et al. Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 9, 993-1001, doi: 10.4161/hv.23800 (2013).
29. International, A. S. S. W. G. o. H. I. V. C. et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12, 607-614, doi: 10.1038/nri3262 (2012).
30. Kutsch, O., Benveniste, E. N., Shaw, G. M. & Levy, D. N. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. Journal of virology 76, 8776-8786 (2002).
31. Chou, T. C. Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro. Contributions to gynecology and obstetrics 19, 91-107 (1994).
32. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological reviews 58, 621-681, doi: 10.1124/pr.58.3.10 (2006).
33. Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22, 27-55 (1984).
34. Spina, C. A. et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 9, e1003834, doi: 10.1371/journal.ppat.1003834 (2013).
35. Lopez-Cabrera, M. et al. Transcriptional regulation of the gene encoding the human C-type lectin leukocyte receptor AIM/CD69 and functional characterization of its tumor necrosis factor-alpha-responsive elements. J Biol Chem 270, 21545-21551 (1995).
36. Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491-501, doi: 10.1016/j.immuni.2012.01.014 (2012).
37. Jones, R. B. et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog 10, e1004287, doi: 10.1371/journal.ppat.1004287 (2014).
38. Wightman, F., Ellenberg, P., Churchill, M. & Lewin, S. R. HDAC inhibitors in HIV. Immunol Cell Biol 90, 47-54, doi: 10.1038/icb.2011.95 (2012).
39. Wei, D. G. et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10, e1004071, doi: 10.1371/journal.ppat.1004071 (2014).
40. Van Lint, C., Bouchat, S. & Marcello, A. HIV-1 transcription and latency: an update. Retrovirology 10, 67, doi: 10.1186/1742-4690-10-67 (2013).
41. Butera, S. T., Perez, V. L., Wu, B. Y., Nabel, G. J. & Folks, T. M. Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection. Journal of virology 65, 4645-4653 (1991).
42. Duh, E. J., Maury, W. J., Folks, T. M., Fauci, A. S. & Rabson, A. B. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proceedings of the National Academy of Sciences of the United States of America 86, 5974-5978 (1989).
43. Folks, T. M., Justement, J., Kinter, A., Dinarello, C. A. & Fauci, A. S. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238, 800-802 (1987).
44. Folks, T. M. et al. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol 140, 1117-1122 (1988).
45. Perez, V. L. et al. An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation. J Immunol 147, 3145-3148 (1991).
46. Jordan, A., Bisgrove, D. & Verdin, E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22, 1868-1877, doi: 10.1093/emboj/cdg188 (2003).
47. Jordan, A., Defechereux, P. & Verdin, E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J 20, 1726-1738, doi: 10.1093/emboj/20.7.1726 (2001).
48. Prince, H. M., Bishton, M. J. & Johnstone, R. W. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future oncology 5, 601-612, doi: 10.2217/fon.09.36 (2009).
49. Campbell, G. R., Bruckman, R. S., Chu, Y. L. & Spector, S. A. Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1. J Biol Chem, doi: 10.1074/jbc.M114.605428 (2014).
50. Clouse, K. A. et al. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. Journal of immunology 142, 431-438 (1989).
51. Folks, T. M. et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proceedings of the National Academy of Sciences of the United States of America 86, 2365-2368 (1989).
52. Garcia-Merino, I. et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology 6, 27, doi: 10.1186/1742-4690-6-27 (2009).